NICE recommends Revlimid for newly diagnosed multiple myeloma patients
Cost-effectiveness agency initially turned down the drug in this setting
Read Moreby Lucy Parsons | Jan 27, 2021 | News | 0
Cost-effectiveness agency initially turned down the drug in this setting
Read Moreby Selina McKee | Sep 9, 2020 | News | 0
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Read Moreby Anna Smith | Feb 27, 2020 | News | 0
The decision brings a new option to the market for around 900 patients.
Read Moreby Anna Smith | May 17, 2019 | News | 0
The new indication will benefit approximately 2,100 patients.
Read Moreby Selina McKee | Jul 28, 2017 | News | 0
Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation.
Read Moreby Selina McKee | Jul 6, 2017 | News | 0
US regulators have placed on clinical hold three studies testing the immunotherapy Keytruda in combination with other therapies for multiple myeloma because of patient deaths.
Read Moreby Selina McKee | Mar 17, 2017 | News | 0
Myeloma UK has launched a ground-breaking immunotherapy trial which aims to modulate the immune system to target myeloma.
Read Moreby Selina McKee | Feb 27, 2017 | News | 0
European regulators have expanded the scope of Celgene’s Revlimid to include its use as monotherapy for the maintenance treatment of adults with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).
Read Moreby Selina McKee | Dec 19, 2016 | News | 0
The market for cancer immunotherapies is set to swell more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, with a rapid compound annual growth rate of 23.9 percent, predicts business intelligence provider GBI Research.
Read Moreby Selina McKee | Nov 14, 2016 | News | 0
Patients with multiple myeloma are being barred from routine access on the NHS to Celgene’s Revlimid and Amgen’s Kyprolis in the second-line setting.
Read Moreby Selina McKee | Aug 1, 2016 | News | 0
Around 300 patients with multiple myeloma in Wales will get National Health Service access to treatment with Celgene’s Revlimid after the drug was recommended for first-line use by cost regulators.
Read Moreby Selina McKee | Jul 18, 2016 | News | 0
Celgene’s Revlimid has been approved by European regulators to treat patients with relapsed/refractory Mantle Cell Lymphoma (MCL), a rare sub-type of aggressive non-Hodgkin’s lymphoma (NHL).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
